Seoul: A groundbreaking temporary "tattoo" could soon provide partygoers with a discreet method to detect drugs commonly used to spike drinks in public venues like bars and clubs. This innovative technology is particularly aimed at identifying drugs such as Rohypnol, also known as a "roofie," and GHB, often referred to as "liquid ecstasy" or "fantasy." These substances are frequently used in nightlife settings, though they are illegal in countries including the United States, UK, and Australia.
According to Deutsche Welle, the new rapid test developed by materials scientists funded by the South Korean government offers a safer alternative to existing methods. Unlike current products that require dipping strips into drinks, leading to potential delays and increased vulnerability, this new method operates almost instantaneously. The product, resembling a tattoo but actually a removable sticker, is embedded with a solution containing an iodide indicator called BHEI. When exposed to GHB, the indicator changes from yellow to red, effectively alerting the wearer to the presence of the drug.
The stickers have demonstrated a rapid response to GHB exposure in various beverages, including whisky, vodka, beer, and coffee. The technology is sensitive enough to detect as little as 0.01 milligrams of GHB per milliliter. The development team emphasizes that this innovation provides a proactive approach to preventing drug-facilitated sexual assault, promoting personal safety, and fostering awareness in environments considered high-risk.
While promising, the sticker technology is not without its challenges. Similar attempts in the past, such as the fluorescent sensor platform from the National University of Singapore and a testing disc from a US startup, highlight the need for further refinement before these products reach the market. Forensic toxicologist Kabrena Rodda warns of potential false positives with spot testing methods, which could lead to unnecessary avoidance of safe drinks and increase anxiety over potential drink spiking.
Despite these challenges, the new sticker test is being praised as an important advancement. A venture company has been established to bring the product to market in South Korea, although customization and adaptability to other drugs remain limited. Gyeong-Ji Kim, the lead author of the study, acknowledges that while customization is somewhat constrained, the potential exists for incorporating receptors for other substances, such as opioids or synthetic cannabinoids, into future iterations of the tattoo sticker platform.